Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - implications for renal H+, K+-ATPases

(2016) N. R. Srinivas   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

(2015) D. R. Scott et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology

(2015) L. Lundell et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

(2014) S. Sahara et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

(2014) Mitsushige Sugimoto et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

(2014) Kazunari Murakami et al.   GASTROENTEROLOGY

Gastric carcinoids after long-term use of a proton pump inhibitor

(2012) C. S. Jianu et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin

(2012) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Development of a Novel, Fully-Automated Genotyping System: Principle and Applications

(2012) Shun-ichi Suzuki et al.   SENSORS

Long-Term Acid Inhibition: Benefits and Harms

(2011) Bojan Tepeš   DIGESTIVE DISEASES

Adverse Effects of Long-Term Proton Pump Inhibitor Therapy

(2011) Edward Sheen et al.   DIGESTIVE DISEASES AND SCIENCES

Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor

(2011) Constantin S Jianu et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking

(2010) Margareta Ramsjö et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

(2008) Katsuyoshi Sugimoto et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY